Phase 1 clinical trial of ART-001
Latest Information Update: 06 Jun 2025
At a glance
- Drugs ART-001-AccurEdit-Therapeutics (Primary)
- Indications Amyloidosis; Polyneuropathy; Transthyretin-related hereditary amyloidosis
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 06 Jun 2025 Status changed from not stated to planning.
- 06 Jun 2025 New trial record
- 29 Aug 2024 According to AccurEdit Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART001, intended for the treatment of transthyretin (ATTR) amyloidosis with polyneuropathy.